Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ribociclib succinate/letrozole

View Patient Information
An orally available co-packaged agent combination of the succinate salt form of ribociclib, a cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6, and letrozole, a nonsteroidal inhibitor of estrogen synthesis, with antineoplastic activity. Upon oral administration, ribociclib specifically inhibits CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Kisqali and Femara co-pack
Kisqali/Femara
ribociclib succinate + letrozole
ribociclib succinate and letrozole co-pack
ribociclib succinate plus letrozole
ribociclib succinate-letrozole
ribociclib succinate-letrozole regimen
ribociclib/letrozole
US brand name:Kisqali Femara Co-Pack
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search